Share-Based Compensation - Summary of Stock Option Activity (Detail) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($) $ / shares shares
Share-Based Payment Arrangement [Abstract]
Outstanding stock options, Beginning balance	7,547
Options granted	1,479
Options exercised	(527)
Options forfeited	(208)
Options expired	(186)
Awards transferred to ZimVie in the spinoff	(431)
Adjustment to Zimmer Biomet awards related to the spin-off of ZimVie	270
Outstanding stock options, Ending Balance	7,944
Number of outstanding options, Vested or expected to vest	7,779
Exercisable, Stock options	5,196
Outstanding Weighted average exercise price, Beginning Balance | $ / shares	$ 125.32
Options granted, Weighted average exercise price | $ / shares	117.04
Options exercised, Weighted average exercise price | $ / shares	82.35
Options forfeited, Weighted average exercise price | $ / shares	132.38
Options expired, Weighted average exercise price | $ / shares	138.54
Awards transferred to ZimVie in the spinoff, Weighted Average Exercise Price | $ / shares	134.66
Outstanding Weighted average exercise price, ending Balance | $ / shares	121.94
Outstanding Weighted average exercise price, Vested or expected to vest | $ / shares	121.70
Exercisable, Weighted average exercise price | $ / shares	$ 116.05
Weighted Average Remaining Contractual Life, Outstanding at December 31, 2022	5 years 10 months 24 days
Weighted Average Remaining Contractual Life, Vested or expected to vest as of December 31, 2022	5 years 9 months 18 days
Weighted Average Remaining Contractual Life, Exercisable at December 31, 2022	4 years 7 months 6 days
Intrinsic Value, Outstanding at December 31, 2022 | $	$ 99.7
Intrinsic Value, Vested or expected to vest as of December 31, 2022 | $	98.7
Intrinsic Value, Exercisable at December 31, 2022 | $	$ 83.2